Caracterización de formas cristalinas de Pirazinamida 500 mg en tabletas por calorimetría diferencial de barrido
No Thumbnail Available
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
El presente trabajo tuvo como objetivo la caracterización de las formas cristalinas de pirazinamida 500 mg en tabletas mediante calorimetría diferencial de barrido (DSC); trabajándose en un rango de temperatura de 20 a 300°C, con rampa de calentamiento de 10 °C/min y flujo de nitrógeno de 50 mL/min, usando un estándar secundario de pirazinamida y tabletas de 500 mg de este medicamento de 2 laboratorios multifuentes identificados como M1 y M2. En los resultados obtenidos en los termogramas, se observan las curvas del estándar y del medicamento referente; muestran a 152 °C una endoterma que representa la pérdida de humedad absorbida y a 190 °C se evidencia una endoterma característica del principio activo; seguido del evento endotérmico, se evidencia una transición vítrea que representa el cambio conformacional y degradación del principio activo. Se caracterizó las formas cristalinas de pirazinamida 500 mg en tabletas mediante calorimetría diferencial de barrido determinando que tanto el medicamento multifuente 1 como el multifuente 2 presentan una forma cristalina alfa, la cuales son metaestables
ABSTRACT The objective of this work was to characterize the crystalline forms of pyrazinamide 500 mg in tablets by means of differential scanning calorimetry (DSC); working in a temperature range of 20 to 300°C, with a heating ramp of 10°C/min and a nitrogen flow of 50 mL/min, using a secondary standard of pyrazinamide and 500 mg tablets of this drug from 2 laboratories multisources identified as M1 and M2. In the results obtained in the thermograms, the curves of the standard and the reference drug are observed; show at 152 °C an endotherm that represents the loss of absorbed moisture and at 190 °C a characteristic endotherm of the active ingredient is evidenced; Following the endothermic event, a glass transition is evidenced, which represents the conformational change and degradation of the active ingredient. The crystalline forms of pyrazinamide 500 mg in tablets were characterized by differential scanning calorimetry, determining that both multisource drug 1 and multisource drug 2 have an alpha crystalline form, which are metastable.
ABSTRACT The objective of this work was to characterize the crystalline forms of pyrazinamide 500 mg in tablets by means of differential scanning calorimetry (DSC); working in a temperature range of 20 to 300°C, with a heating ramp of 10°C/min and a nitrogen flow of 50 mL/min, using a secondary standard of pyrazinamide and 500 mg tablets of this drug from 2 laboratories multisources identified as M1 and M2. In the results obtained in the thermograms, the curves of the standard and the reference drug are observed; show at 152 °C an endotherm that represents the loss of absorbed moisture and at 190 °C a characteristic endotherm of the active ingredient is evidenced; Following the endothermic event, a glass transition is evidenced, which represents the conformational change and degradation of the active ingredient. The crystalline forms of pyrazinamide 500 mg in tablets were characterized by differential scanning calorimetry, determining that both multisource drug 1 and multisource drug 2 have an alpha crystalline form, which are metastable.
Description
Keywords
Calorimetría diferencial de barrido, Antituberculoso, Pirazinamida,
Polimorfismo.